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Abstract
Background: In Ethiopia, measles case-based surveillance was introduced in 2004 as one strategy for measles
control by laboratory confirmation of suspected cases. In this article, epidemiological distribution of laboratory-
confirmed measles cases were reported from the Southern Nation Nationalities and Peoples Region (SNNPR) of
Ethiopia between 2007 and 2014, as the region is one of the highly measles affected areas in Ethiopia.
Method: A serum sample was collected from all measles suspected cases, and patient information was captured by
case reporting format (CRF). Samples were transported to the National Measles Laboratory for Measles IgM testing
by ELISA technique. Data entry and analysis were done using Epi-Info 3.5.4 software.
Result: A total of 4810 samples were tested for measles IgM using ELISA technique and 1507 (31.3%) were found
positive during 2007–2014 in SNNPR of Ethiopia. Patients with age 1–4 years were the most affected regardless of
sex. The incidence of measles confirmed cases increased from 15 in 2007 to 180 in 2013 per million population. The
highest percentage of laboratory-confirmed cases were found in 2014. Measles was found distributed throughout
the regional state.
Conclusion: Measles was found a public health important disease in SNNPR of Ethiopia, mostly affecting children
1–4 years. The incidence of measles cases is increasing from time to time. Additional research to determine the
genotype of circulating measles virus, knowledge, attitude and practice of professionals and the population for
measles vaccination and infection in the region is important. A wide age group measles vaccination campaign is
highly recommended.
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Background
Measles is an acute, highly infectious viral disease caused
by morbillivirus in the family Paramyxoviridae for which
humans are the only reservoirs. The primary transmis-
sion is person-to-person via aerosolized droplets or by
direct contact with nasal and throat secretions of
infected persons. When measles virus infect a non-
immune population, nearly 100% of individuals will
become infected and develop clinical illness. The incuba-
tion period of measles is about 10 to 12 days. Malnourished
children are at higher risk of developing complications and
mortality from this infection [1].
Measles remained as one of the vaccine-preventable
diseases still causing major mortality and morbidity in
developing countries. The severity of disease is higher
among infants and adults than children and results
complications from viral replication or bacterial super-
infection including otitis media, pneumonia, laryngo-
tracheo-bronchitis (croup), diarrhoea, encephalitis and
blindness [2].
Global measles control has been very successful.
Worldwide, an estimated 60% measles-associated mor-
tality reduction with 75% reduction in the African region
were achieved following implementation of the 2001
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World Health Organization (WHO) member states goal
of 50% measles mortality reduction by 2005, compared
with the 1999 estimate [3–5]. Following this progress,
the WHO African region approved a new goal in 2006
to achieve a 90% measles-associated mortality reduction
by 2010, compared with the 2000 estimate. In 2008,
reported measles cases had decreased by 93% and an
estimated 92% measles-associated mortality reduction
was found [4, 5].
The African region technical advisory group (TAG)
reviewed the measles control progress and set a new mea-
sles reduction target called a pre-elimination goal, aimed
to reduce the annual incidence to <5 measles cases per
million population in all African countries [1, 6]. National
and sub-national level measles data analysis was put as a
vital way to make informed decisions on progress towards
achieving this goal.
In 1980, Ethiopia introduced measles vaccination as
part of the routine extended program of immunization
(EPI) with first dose administration at 9 months of age.
The measles vaccine coverage remained below 50% until
2003. Following augmented efforts to improve perform-
ance by the Federal Ministry of Health (FMOH) and EPI
support partners, administrative measles vaccination
coverage improved from 44% in 2003 to 81% in 2010 at
the national level [7].
In 2014, there were 114,900 measles deaths globally [8].
In 2013, an estimated 21.5 million children were not vac-
cinated against measles at the 9th month of age. Of these,
more than 60% children were from India (6.4 million),
Nigeria (2.7 million), Pakistan (1.7 million), Ethiopia (1.1
million), Indonesia (0.7 million) and Democratic Republic
of Congo (0.7 million). More than 70% of the global
measles-related deaths occurred in these 6 countries in
2013 showing developing countries affected utmost [9].
Although the vaccination coverage is increasing from
year to year in Ethiopia, the country continued reporting
a higher number of measles cases and outbreaks in all
regional states and city administrations. According to
WHO, Ethiopia is experiencing an ongoing measles out-
break by reporting more than 14,000 confirmed cases in
2014 only [10] and being one of the world countries that
experienced large outbreaks in 2009 and 2010 according
to CDC report [11]. The purpose of this study is to
characterize the epidemiology measles virus with greater
emphasis on laboratory-confirmed cases and to provide
evidence for the decision-making process in an effort to
eliminate measles in the Southern Nations Nationalities
and Peoples’ Region (SNNPR) of Ethiopia.
Methods
Study setting
The study was carried out in SNNPR. SNNPR is the third
most populous region in Ethiopia, with a population of 15
million, a growth rate of 2.9 per annum and a child mor-
tality rate of 85 per 1000 livebirths in 2007 and the region
covers an estimated area of 105,887.18 square kilometers,
[12]. The SNNPR is located in South Western part of
Ethiopia. Administratively, the region is divided in to
zones, that further divided as woredas and kebeles. The
region shares common boundaries with Oromia in
Eastern and Northern, Gambella in West, South Sudan
Republic in South-Western and Kenya in Southern
(Fig. 1).
Study population and case definition
The WHO African Regional Office/AfRO measles case-
based surveillance guidelines were adjusted for use in
Ethiopia as well in SNNPR as of 2004. All age groups
were included in this study using the case definition. A
suspected measles case is defined as any person with
generalized maculopapular rash and fever plus one of
the following: cough or coryza (runny nose) or conjunc-
tivitis (red eyes) or any person a clinician suspects to
have measles. Laboratory confirmed measles case is a
case that has recent measles virus-specific immuno-
globulin M (IgM) antibody in blood by serological test
and did not receive a measles vaccine within the last
30 days. Confirmed measles by epidemiological linkage
is a measles case from which a specimen had not taken
for serologic confirmation but linked (in place, person
and time) to lab-confirmed cases. Clinically confirmed/
compatible cases are individuals without blood and no
epi-linkage with lab-confirmed cases or have equivocal
measles IgM test results in blood, this will be high in
seasons of no lab testing. Discarded cases are individuals
with negative measles IgM lab result or IgM positive
with a vaccination history within 2 weeks of blood
drawn. Measles outbreaks are defined as the occurrence
of 3 or more lab-confirmed measles cases reported from
the same district or catchment area of a health facility
with rash onset within 4 weeks. Incidence is the total
number of confirmed measles cases by lab confirmation
and epidemiological linkage per million population [1].
Specimen collection and transportation
At first contact with suspected cases, about 5 ml blood
was drawn by venipuncture into a sterile anticoagulant-
free tube. Almost all (99.6%) samples in this study were
collected within 28 days of rash onset from suspected
cases. Serum was separated from whole blood and trans-
ferred aseptically to a sterile vial. The serum specimens
with completed case reporting form (CRF) were trans-
ported in cold boxes to the testing laboratory, National
Measles Laboratory is located in Ethiopian Public Health
Institute (EPHI), Addis Ababa, Ethiopia.
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Laboratory method and quality assurance
Enzyme-linked immunosorbent assay (ELISA) technique
was done for measles-specific IgM antibody identification
according to the manufacturer’s protocol (Enzygnost® Anti-
Measles-Virus/IgM kit; Siemens Diagnostics Products,
Marburg, Germany). Samples and reagents were manually
dispensed using a micropipette (Gilson S.A.S., France). A 5
micro liter (μl) serum was diluted with 205 μl working so-
lution (diluted blue solution and reconstituted rheumatoid
factor). 150 μl of this diluted solution was transferred to a
double (antigen coated and control) well of ELISA plate
and incubated for an hour to allow patient’s antibody (if
any) bind antigen coated surface. Test plates were washed
using a microplate washer (Denley Instruments Ltd,
England) to remove unbound antibody. 100 μl of enzyme-
labeled antihuman IgM working solution was added to
each well and incubated for an hour to allow the attach-
ment of enzyme-labeled antibody with patient’s antibody,
then washed to remove unbound antihuman IgM.
100 μl chromogen substrate solution was added to
each well and allowed 30 min for enzyme labeled
antibody (if any) to break the substrate and produce a
color change. The optical densities (OD) were read at
450 nm with a 630-nm reference filter using an
ELISA reader (Labsystems, Finland). The change in
Od was found by subtracting the OD of the control
well from OD of antigen well. Samples with a change
in OD <0.1 were recoded negative and >0.2 were
positive and equivocal when OD between 0.1 and 0.2.
Samples with equivocal results were retested to be re-
ported. Based on the surveillance protocol, samples
with equivocal or negative measles IgM result were
further tested for rubella virus IgM.
The laboratory was evaluated regularly for quality con-
trol, sends 10% quality control (QC) samples quarterly,
receives external quality assurance (EQA) proficiency
test (PT) samples annually and accredited yearly by
WHO Global Measles and Rubella Laboratory Network
for the purpose of generating credible lab results for the
program. Job aids and standard operational procedure
(SOP) were available in lab.
During this study period, the lab maintain its accredit-
ation, scored ≥ 95% accuracy for both QC and PT sam-
ples and applied internal and external control samples
with each run. Patient results were reported when the
run was valid based on the controls used. Due to kit
shortage, samples collected after mid October 2014 were
not tested for measles IgM antibody.
Data entry and analysis
Patient information and laboratory results were entered
into Epi-Info database. In the surveillance, data were
shared every Fri-day to the FMOH, WHO-Ethiopia,
WHO-AfRO and all concerned for action . Data for this
study purpose, 2007–2014, were extracted and analyzed
using Epi-Info (Version 3.5.4. CDC, Atlanta, USA).
Fig. 1 Map of Ethiopia Showing the Relative Location of SNNPR and its Administrative Zones with Distribution of Measles Cases (Source:
WIKIPEDIA, the free Encyclopedia at https://en.wikipedia.org/wiki/Regions_of_Ethiopia)
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Results
A total of 4810 suspected patients were notified with
blood and tested in the lab during 2007–2014 from
SNNPR State of Ethiopia. The mean age of study partici-
pants was 6.3 years ranging from a month to 84 years
with 51.6% males. Evidence on sex was unavailable for
20 cases. The highest proportion of tested persons (36%)
were children 1–4 years age followed by children 5–9
years (29.3%). The highest number of samples (976) were
collected in 2013 and the lowest (466) in 2007 (Table 1).
The highest (656) and lowest (208) number of cases had
onset in January and September respectively. A higher
number of samples were collected from Sidama (912)
and Guraghe (700) zones of SNNPR, Ethiopia.
Among tested samples, a total of 1507 (31.3%) samples
were found positive for measles-specific IgM and the
rest 3196 (66.4%) and 107 (2.2%) were negatives and
equivocal (compatibles) respectively (Table 1). Of 1507
laboratory confirmed measles cases, 52.3% (788) were
males and sex was unavailable for 8 (0.5%) cases. The
lowest number of positives (77) and positive proportions
(14.2%) were found in 2008 and the highest number of
positives (348) were found in 2013. The highest propor-
tion of positives (52.4%) was found in 2014 (Fig. 2).
Among the total 3,303 measles IgM negatives and
equivocal, 572 (17.3%) were found positive for rubella
virus-specific IgM antibody, another rash febrile illness.
Most of the rubella positive cases were found in the
period 2012–2014 with no zero reports in all the study
years (13 – 227 reports) (Fig. 3).
Most of the measles cases occurred among children
less than 15 years (Fig. 4). Likewise, rubella virus specific
IgM antibody was detected among non-measles positive
cases and was found higher from children up to 15 years
of age (data not shown). Both measles and rubella con-
firmed cases decrease after the age of 15 years.
Although measles was most common among children
less than 15 years of age, the highest and lowest positive
proportions (%) were found from patients above 15 years
and infants respectively throughout the study period
(Fig. 2).
Measles was found endemic throughout the year and
all zones of the region with the highest number (246) of
positives in January and the lowest (39) in June during
the study period (Fig. 5).
Similar to the laboratory confirmed cases, the epidemi-
ologically linked measles cases increased linearly through
the study period, from 36 cases in 2007 to 2928 in 2013
and the highest number of clinically confirmed cases
were in 2014 (Fig. 3).
In this study, the incidence of measles cases was found
increasing among all age groups with a total of 15 in
2007 to 180 in 2013 per million population and the inci-
dence decreased as the patient age increased in SNNPR
(Fig. 6).
Discussion
Analysis of the measles case-based surveillance labora-
tory data in SNNPR, Ethiopia for 2007–2014 revealed
that 4810 suspected cases were investigated with an
average 601 blood samples collected and tested per year.
This was much lower than the mean number of annually
notified cases of 1637 South West Nigeria, although the
population is also double of SNNPR [13].
Of the laboratory tested cases, 31.3% were confirmed
measles, showing the circulation of measles virus in the
community or improved case capturing due to case sen-
sitive surveillance in the region. This positivity rate was
much higher than a study finding from South West
Nigeria [13] and Zimbabwe [14]. The incidence of mea-
sles cases was found decreased as the age group in-
creased, this is expected as measles infection will result
in life-long immunity.
The number and proportion of lab-confirmed measles
cases were found fluctuating but the incidence of
confirmed measles (lab plus epi-linked) cases was found
increasing strictly in the study years, 15 in 2007 to 180
in 2013 (higher than the pre-elimination target of <5
cases per million population, Fig. 6). Laboratory con-
firmed cases increased from 137 in 2007 to 295 in 2014,
but lower in 2012. The frequency of measles cases
Table 1 Distribution of Measles Tested Cases in Different
Variables in SNNPR, 2007-2014
Variables Measles IgM Test Result Total
Category Positive Negative Equivocal
Sex Male 788 1638 55 2481
Female 711 1546 52 2309
Unavailable 8 12 0 20
Age Group <1 Year 113 389 11 513
1–4 Years 469 1228 33 1730
5–9 Years 412 975 24 1411
10–14 Years 300 391 25 716
≥15 Years 184 164 10 358
Missed 29 49 4 82
Years 2007 137 316 13 466
2008 77 449 18 544
2009 85 393 6 484
2010 255 343 17 615
2011 203 282 14 499
2012 107 546 10 663
2013 348 611 17 976
2014 295 256 12 563
Total 1507 3196 107 4810
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fluctuated between different age groups (Fig. 4). This
might be related to inconsistency in the Supplemental
Immunization Activities (SIAs) coverage and time inter-
val conducted and age of targeted children for vaccin-
ation. This was similar finding with a study in Nigeria
where a pattern of high incidence followed by a low inci-
dence was common [3].
Similar to the finding of a study from South West
Nigeria [13], the highest number of measles confirmed
cases occurred among children 1–4 years followed by 5–
9 years children (Table 1, Fig. 6). Although the highest
proportion (%) of measles positive cases was found
among young adults (aged ≥ 15 years) each year (Fig. 2),
the incidence of measles found among this age group
was lowest (Fig. 6). Measles in the adults suggests an im-
munity gap likely due to the accumulation of susceptible
individuals over several years from sub-optimal vaccin-
ation coverage in the previous years.
Most of the lab-confirmed measles cases occurred in
the dry season (October-February), with the peak in
January and February. This is in line with an earlier
study finding from Abia State of Nigeria [15] and WHO
report of measles infection trend [16]. This might be
related with the more cultural gatherings (weddings,
holydays) in this season that favors measles transmission
in the SNNPR of Ethiopia.
According to WHO-AfRO Measles and Rubella sur-
veillance guideline, measles suspected cases that were
tested and had negative or equivocal result will be tested
for rubella virus-specific IgM, another rash febrile ill-
ness. In this study, 17.3% of non-measles cases were
found positive for rubella virus and children 5–9 years
were affected greatly. This finding was much lower than
a 37.6% positivity rate of rubella from Zimbabwe [17]. In
general, 43.2% of laboratory tested samples were positive
for either measles or rubella. The higher proportion of
Fig. 2 Proportion (%) of Lab Confirmed Measles by Age Group of Patients, SNNPR, Ethiopia, 2007–2014
Fig. 3 Distribution of Lab Tested Persons, Lab Confirmed Measles/Rubella, Epidemiologically Linked, Clinically Confirmed and Discarded Measles
Cases, SNNPR, Ethiopia, 2007–2014
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samples (56.8%) were found negative or equivocal for
both measles and rubella. This may be due to other fe-
brile rash illnesses in the community by infectious and
non-infectious agents.
The highest number of clinically confirmed and the low-
est number of epidemiologically linked measles cases in
2014 was due to a shortage of kit in the fourth quarter and
the incidence of measles cases was seen dropped in this year
as no sample was tested after the mid of October (Figs. 3
and 6). This obviously true that as the lab testing stops, clin-
ical classification of cases will be increased and there will be
no epidemiologically linked cases in this season.
In general, decreased incidence is normal to increasing
vaccine coverage report of a specific disease. Unfortunately
in SNNPR both reports of administrative measles vaccine
coverage and measles incidence were found increasing at
the same time [18]. This may be related to the improved
case detection through time due to increased coverage,
quality, and sensitivity as part of massive health service
expansion in Ethiopia as well in SNNPR [19]. The efficacy
and cold chain condition of vaccine needs further investi-
gation in such high coverage reports and increasing case
detection.
Our study had the following limitations. First, data
presented here was mainly related to the lab-confirmed
measles cases giving little emphasis to clinically con-
firmed and epi-linked cases as the details of these not
submitted to the lab. Second, there was no data on the
clinical presentation and severity of cases, vaccination
status and case fatality rate as these information rarely
submitted to the laboratory.
Conclusion
In SNNPR, measles continued as an important public
health problem. The incidence of confirmed measles was
found increasing from year to year mostly affecting
Fig. 4 Distribution of Lab Confirmed Measles by Age of Patients in Years, SNNPR, Ethiopia, 2007–2014
Fig. 5 Distribution of Lab Confirmed Measles Patients by Study Years and Months, SNNPR, Ethiopia, 2007–2014
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children aged a month to 4 years. Measles is a seasonal
infection reaching a peak during January and February.
We recommend wide age range measles campaign for
the region and additional study to understand the know-
ledge, attitude, and practice of the professionals and the
population for measles infection and vaccination is
advisable. Finally genotyping of circulating measles virus
strain is paramount important.
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